

Title (en)

ATTENUATED VIRUSES USEFUL FOR VACCINES

Title (de)

FÜR IMPFSTOFFE GEEIGNETE ABGESCHWÄCHTE VIREN

Title (fr)

VIRUS ATTENUES UTILES POUR DES VACCINS

Publication

EP 3431099 B1 20240103 (EN)

Application

EP 18177156 A 20080331

Priority

- US 90938907 P 20070330
- EP 08799746 A 20080331
- US 2008058952 W 20080331
- US 6866608 P 20080307

Abstract (en)

[origin: WO2008121992A2] This invention provides an attenuated virus which comprises a modified viral genome containing nucleotide substitutions engineered in multiple locations in the genome, wherein the substitutions introduce synonymous deoptimized codons into the genome. The instant attenuated virus may be used in a vaccine composition for inducing a protective immune response in a subject. The invention also provides a method of synthesizing the instant attenuated virus. Further, this invention further provides a method for preventing a subject from becoming afflicted with a virus-associated disease comprising administering to the subject a prophylactically effective dose of a vaccine composition comprising the instant attenuated virus.

IPC 8 full level

A61K 39/13 (2006.01); **A61K 39/12** (2006.01)

CPC (source: EP KR US)

A61K 39/12 (2013.01 - EP US); **A61K 39/13** (2013.01 - KR US); **A61K 39/145** (2013.01 - US); **A61P 31/12** (2018.01 - EP);
A61P 31/14 (2018.01 - EP); **A61P 31/16** (2018.01 - EP); **A61P 31/18** (2018.01 - EP); **A61P 31/20** (2018.01 - EP); **A61P 31/22** (2018.01 - EP);
A61P 37/04 (2018.01 - EP); **C07K 14/005** (2013.01 - US); **C12N 7/00** (2013.01 - EP US); **A61K 2039/5254** (2013.01 - EP US);
C12N 2720/12361 (2013.01 - EP US); **C12N 2740/15061** (2013.01 - EP US); **C12N 2760/16061** (2013.01 - EP US);
C12N 2760/16121 (2013.01 - US); **C12N 2760/16134** (2013.01 - US); **C12N 2760/16162** (2013.01 - US); **C12N 2770/20061** (2013.01 - EP US);
C12N 2770/24161 (2013.01 - EP US); **C12N 2770/32061** (2013.01 - EP US); **C12N 2770/32621** (2013.01 - US); **C12N 2770/32634** (2013.01 - US);
C12N 2770/32661 (2013.01 - EP US); **C12N 2770/32662** (2013.01 - US); **C12N 2770/32671** (2013.01 - US); **C12N 2770/32721** (2013.01 - US);
C12N 2770/32761 (2013.01 - EP US); **C12N 2770/32762** (2013.01 - US); **Y02A 50/30** (2018.01 - EP US)

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

Designated extension state (EPC)

AL BA MK RS

DOCDB simple family (publication)

WO 2008121992 A2 20081009; WO 2008121992 A3 20090226; AU 2008232491 A1 20081009; AU 2008232491 B2 20140522;
BR PI0809600 A2 20160712; BR PI0809600 B1 20230124; CA 2682089 A1 20081009; CA 2682089 C 20190312; CN 103476425 A 20131225;
CN 103476425 B 20150715; DK 2139515 T3 20180827; DK 2139515 T4 20240304; EP 2139515 A2 20100106; EP 2139515 A4 20110706;
EP 2139515 B1 20180613; EP 2139515 B2 20231220; EP 3431099 A1 20190123; EP 3431099 B1 20240103; EP 4368202 A2 20240515;
EP 4368202 A3 20240821; HR P20181319 T1 20181019; HR P20181319 T4 20240216; JP 2010523086 A 20100715;
JP 2015091247 A 20150514; JP 5733976 B2 20150610; KR 101621100 B1 20160513; KR 20100019423 A 20100218;
MX 2009010549 A 20100315; MX 349825 B 20170815; PL 2139515 T3 20181130; PL 2139515 T5 20240408; US 10023845 B2 20180717;
US 11162080 B2 20211102; US 2010209454 A1 20100819; US 2017067030 A1 20170309; US 2019010469 A1 20190110;
US 2022298492 A1 20220922; US 2024228981 A1 20240711; US 9476032 B2 20161025

DOCDB simple family (application)

US 2008058952 W 20080331; AU 2008232491 A 20080331; BR PI0809600 A 20080331; CA 2682089 A 20080331;
CN 200880018001 A 20080331; DK 08799746 T 20080331; EP 08799746 A 20080331; EP 18177156 A 20080331; EP 23219605 A 20080331;
HR P20181319 T 20080331; JP 2010501289 A 20080331; JP 2014257141 A 20141219; KR 20097022782 A 20080331;
MX 2009010549 A 20080331; MX 2014010788 A 20080331; PL 08799746 T 20080331; US 201615258584 A 20160907;
US 201816036348 A 20180716; US 202117513032 A 20211028; US 202318512196 A 20231117; US 59417308 A 20080331